.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Daiichi Sankyo
US Army
Covington
Argus Health
UBS
McKesson
Mallinckrodt
Accenture
Boehringer Ingelheim

Generated: December 15, 2017

DrugPatentWatch Database Preview

CABOMETYX Drug Profile

« Back to Dashboard

When do Cabometyx patents expire, and when can generic versions of Cabometyx launch?

Cabometyx is a drug marketed by Exelixis Inc and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and twenty-nine patent family members in twenty-eight countries and twelve supplementary protection certificates in nine countries.

The generic ingredient in CABOMETYX is cabozantinib s-malate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the cabozantinib s-malate profile page.

Summary for CABOMETYX

Drug patent expirations by year for CABOMETYX

Pharmacology for CABOMETYX

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Exelixis IncCABOMETYXcabozantinib s-malateTABLET;ORAL208692-001Apr 25, 2016RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Exelixis IncCABOMETYXcabozantinib s-malateTABLET;ORAL208692-003Apr 25, 2016RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Exelixis IncCABOMETYXcabozantinib s-malateTABLET;ORAL208692-002Apr 25, 2016RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Exelixis IncCABOMETYXcabozantinib s-malateTABLET;ORAL208692-001Apr 25, 2016RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Exelixis IncCABOMETYXcabozantinib s-malateTABLET;ORAL208692-002Apr 25, 2016RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Exelixis IncCABOMETYXcabozantinib s-malateTABLET;ORAL208692-002Apr 25, 2016RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Exelixis IncCABOMETYXcabozantinib s-malateTABLET;ORAL208692-003Apr 25, 2016RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Exelixis IncCABOMETYXcabozantinib s-malateTABLET;ORAL208692-003Apr 25, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Exelixis IncCABOMETYXcabozantinib s-malateTABLET;ORAL208692-001Apr 25, 2016RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Exelixis IncCABOMETYXcabozantinib s-malateTABLET;ORAL208692-001Apr 25, 2016RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: CABOMETYX

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,014,155,378► Subscribe
8,476,298c-Met modulators and method of use► Subscribe
9,174,947c-Met modulators and methods of use► Subscribe
9,809,549Malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'(4-fluorophenyl)cycl- opropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer► Subscribe
8,178,532c-Met modulators and method of use► Subscribe
8,067,436c-Met modulators and methods of use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: CABOMETYX

Country Document Number Estimated Expiration
Japan4638436► Subscribe
Japan2014074059► Subscribe
Canada2537812► Subscribe
Japan2011042686► Subscribe
New Zealand618004► Subscribe
Japan5934204► Subscribe
Canada2744997► Subscribe
Poland2210607► Subscribe
TaiwanI511956► Subscribe
New Zealand594594► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CABOMETYX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0678Netherlands► SubscribePRODUCT NAME: CABOZANTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140326
0 50007-2014Slovakia► SubscribePRODUCT NAME: CABOZANTINIB; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140326
00678Netherlands► SubscribePRODUCT NAME: CABOZANTINIB EN ELKE THERAPEUTISCH EQUIVALENTE VORM DAARVAN ZOALS BESCHERMD DOOR HET BASISOCTROOI, WAARONDER FARMACEUTISCH AANVAARDBARE ZOUTEN; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140326
2014033,C2213661Lithuania► SubscribePRODUCT NAME: KABOZANTINIBAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140321
508Luxembourg► SubscribePRODUCT NAME: CABOZANTINIB ET TOUTES LES FORMES THERAPEUTIQUEMENT EQUIVALENTES QUI EN DERIVENT TELLES QUE PROTEGEES PAR LE BREVET DE BASE, Y COMPRIS LES SELS PHARMACEUTIQUEMENT ACCEPTABLES. FIRST REGISTRATION: 20140326
2014033Lithuania► SubscribePRODUCT NAME: CABOZANTINIBUM; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140321
90053-4Sweden► SubscribePRODUCT NAME: CABOZANTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/13/890 20140326
C0067France► SubscribePRODUCT NAME: CABOZANTINIB ET TOUTE FORME THERAPEUTIQUEMENT EQUIVALENTE COUVERTE PAR LE BREVET DE BASE,INCLUANT SES SELS PHARMACEUTIQUEMENT EQUIVALENTS.; REGISTRATION NO/DATE: EU/1/13/890 20140326
2014 00039Denmark► SubscribePRODUCT NAME: CABOZANTINIB, INKLUSIVE FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER CABOZANTINIB (S)-MALAT; REG. NO/DATE: EU/1/13/890/001-003 20140326
2014000091Germany► SubscribePRODUCT NAME: CABOZANTINIB UND JEDES THERAPEUTISCHE AEQUIVALENT HIERVON WIE DURCH DAS GRUNDPATENT GESCHUETZT, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARER SALZE; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140321
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Julphar
Novartis
QuintilesIMS
McKesson
Medtronic
Argus Health
AstraZeneca
Daiichi Sankyo
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot